News

Lymphoma Research Foundation Elects Kristi Hendriks to Esteemed Board of Directors

The Lymphoma Research Foundation – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – today announced the election of Kristi Hendriks of Boston, MA to its Board of Directors. 

Lymphoma Research Foundation Elects New Scientific Advisory Board Members

Lymphoma Research Foundation Elects New Scientific Advisory Board Members Foundation welcomes four world-leading lymphoma experts to contribute to the global impact of the Foundation and guide the Foundation’s research portfolio The Lymphoma Research Foundation is proud to welcome four new…

The U.S. Food and Drug Administration (FDA) Grants Accelerated Approval to Epcoritamab-Bysp (Epkinly) for Relapsed or Refractory Follicular Lymphoma

On June 26, 2024, the U.S. Food and Drug Administration (FDA) announced it has granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines…

Donor Spotlight: Leigh Olson

Major donor, Leigh Olson’s experience with the Lymphoma Research Foundation started in a doctor’s waiting room.

Conquering the Unknowns in Lymphoma

Thomas Habermann, MD, a Professor of Medicine at Mayo Clinic in Rochester, Minnesota, and former Chair of the Lymphoma Research Foundation’s Scientific Advisory Board (SAB) brings passion and drive to every study he works on and every patient he works with.

Where Are They Now? Lymphoma Rounds 15 Years In Review

Since 2008, Lymphoma Rounds programs provide a forum for healthcare professionals to meet regularly and address issues specific to the diagnosis and treatment of their lymphoma patients.

Tackling Obstacles On and Off the Field

In many ways, Timmy Ward is a typical college senior, majoring in sociology and playing football for the Rutgers Scarlet Knights – a Big Ten powerhouse. However, what most people don’t know is what he has had to overcome to get here.

Read the Latest Issue of Pulse: Spring 2024

Dear Friends of LRF, At the Lymphoma Research Foundation, our sights have always beenfixed to the horizon, looking ahead toward our vision of a world withoutlymphoma. Our focus on the future is why we have funded over $80Min lymphoma and…

Meet the 2024 Career Development Award and Postdoctoral Fellowship Research Grantees

The 16 Career Development Award and Postdoctoral Fellowship research grants include projects exploring numerous disease subtypes treatments, including rare disease states like T-cell lymphomas, as well as novel therapeutics.

The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Mantle Cell Lymphoma

On May 30, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received two or more prior lines of…

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.